188 related articles for article (PubMed ID: 31426598)
1. Development of Organelle Replacement Therapy Using a Stearyl-Polyhistidine Peptide against Lysosomal Storage Disease Cells.
Hayashi T; Okamoto R; Kawano T; Iwasaki T
Molecules; 2019 Aug; 24(16):. PubMed ID: 31426598
[TBL] [Abstract][Full Text] [Related]
2. A polylysine-polyhistidine fusion peptide for lysosome-targeted protein delivery.
Iwasaki T; Murakami N; Kawano T
Biochem Biophys Res Commun; 2020 Dec; 533(4):905-912. PubMed ID: 33008588
[TBL] [Abstract][Full Text] [Related]
3. Drug delivery using polyhistidine peptide-modified liposomes that target endogenous lysosome.
Hayashi T; Shinagawa M; Kawano T; Iwasaki T
Biochem Biophys Res Commun; 2018 Jun; 501(3):648-653. PubMed ID: 29746864
[TBL] [Abstract][Full Text] [Related]
4. Stable expression of protective protein/cathepsin A-green fluorescent protein fusion genes in a fibroblastic cell line from a galactosialidosis patient. Model system for revealing the intracellular transport of normal and mutated lysosomal enzymes.
Naganawa Y; Itoh K; Shimmoto M; Kamei S; Takiguchi K; Doi H; Sakuraba H
Biochem J; 1999 Jun; 340 ( Pt 2)(Pt 2):467-74. PubMed ID: 10333491
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders.
Fraldi A; Annunziata F; Lombardi A; Kaiser HJ; Medina DL; Spampanato C; Fedele AO; Polishchuk R; Sorrentino NC; Simons K; Ballabio A
EMBO J; 2010 Nov; 29(21):3607-20. PubMed ID: 20871593
[TBL] [Abstract][Full Text] [Related]
6. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders.
Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S
Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793
[TBL] [Abstract][Full Text] [Related]
7. A lysosome-plasma membrane-sphingolipid axis linking lysosomal storage to cell growth arrest.
Samarani M; Loberto N; Soldà G; Straniero L; Asselta R; Duga S; Lunghi G; Zucca FA; Mauri L; Ciampa MG; Schiumarini D; Bassi R; Giussani P; Chiricozzi E; Prinetti A; Aureli M; Sonnino S
FASEB J; 2018 Oct; 32(10):5685-5702. PubMed ID: 29746165
[TBL] [Abstract][Full Text] [Related]
8. SnapShot: Lysosomal Storage Diseases.
Martina JA; Raben N; Puertollano R
Cell; 2020 Feb; 180(3):602-602.e1. PubMed ID: 32032518
[TBL] [Abstract][Full Text] [Related]
9. Intracellular trafficking of lysosomal proteins and lysosomes.
Hasilik A; Wrocklage C; Schröder B
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S18-33. PubMed ID: 20040308
[TBL] [Abstract][Full Text] [Related]
10. A molecular mechanism to regulate lysosome motility for lysosome positioning and tubulation.
Li X; Rydzewski N; Hider A; Zhang X; Yang J; Wang W; Gao Q; Cheng X; Xu H
Nat Cell Biol; 2016 Apr; 18(4):404-17. PubMed ID: 26950892
[TBL] [Abstract][Full Text] [Related]
11. [Lysosomes and lysosomal storage diseases].
Germain DP
J Soc Biol; 2002; 196(2):127-34. PubMed ID: 12360741
[TBL] [Abstract][Full Text] [Related]
12. Potential Treatment of Lysosomal Storage Disease through Modulation of the Mitochondrial-Lysosomal Axis.
Kuk MU; Lee YH; Kim JW; Hwang SY; Park JT; Park SC
Cells; 2021 Feb; 10(2):. PubMed ID: 33671306
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal integral membrane glycoproteins are expressed at high levels in the inclusion bodies of I-cell disease fibroblasts.
Sandoval IV; Chen JW; Yuan L; August JT
Arch Biochem Biophys; 1989 May; 271(1):157-67. PubMed ID: 2540710
[TBL] [Abstract][Full Text] [Related]
14. Isolation of mast cell secretory lysosomes using flow cytometry.
Rajotte D; Stearns CD; Kabcenell AK
Cytometry A; 2003 Oct; 55(2):94-101. PubMed ID: 14505314
[TBL] [Abstract][Full Text] [Related]
15. Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay-Sachs disease.
Chen Y; Jian J; Hettinghouse A; Zhao X; Setchell KDR; Sun Y; Liu CJ
J Mol Med (Berl); 2018 Dec; 96(12):1359-1373. PubMed ID: 30341570
[TBL] [Abstract][Full Text] [Related]
16. Subcellular Nanorheology Reveals Lysosomal Viscosity as a Reporter for Lysosomal Storage Diseases.
Devany J; Chakraborty K; Krishnan Y
Nano Lett; 2018 Feb; 18(2):1351-1359. PubMed ID: 29313356
[TBL] [Abstract][Full Text] [Related]
17. Estimation and comparison of lysosomal and cytoplasmic pH of human fibroblasts from healthy donors and patients with lysosomal storage diseases.
Ivleva TS; Ogloblina TA; Litinskaya LL; Wiederschain GYa
Biomed Sci; 1991; 2(4):398-402. PubMed ID: 1797144
[TBL] [Abstract][Full Text] [Related]
18. The lysosomal membrane-export of metabolites and beyond.
Rudnik S; Damme M
FEBS J; 2021 Jul; 288(14):4168-4182. PubMed ID: 33067905
[TBL] [Abstract][Full Text] [Related]
19. Liposomal formulations for treating lysosomal storage disorders.
Tomsen-Melero J; Merlo-Mas J; Carreño A; Sala S; Córdoba A; Veciana J; González-Mira E; Ventosa N
Adv Drug Deliv Rev; 2022 Nov; 190():114531. PubMed ID: 36089182
[TBL] [Abstract][Full Text] [Related]
20. ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement.
Garnacho C; Muro S
J Drug Target; 2017; 25(9-10):786-795. PubMed ID: 28665212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
